Humana Inc. shares fell 6.60% to $363.07 in premarket trading on Wednesday, July 29, 2026, after the Louisville-based health insurer lowered its full-year GAAP earnings per share (EPS) guidance. Despite reporting a second-quarter adjusted EPS of $7.61 that beat the consensus estimate of $7.22, the market reacted negatively to the revised outlook and unchanged adjusted guidance, which failed to meet investor expectations for significant upside following strong results from peers like UnitedHealth Group Inc.

The company reported Q2 revenue of $40.89 billion, surpassing the consensus of $40.61 billion and rising from $32.39 billion a year ago. While the top-line performance was robust, Humana lowered its fiscal 2026 GAAP EPS guidance to at least $6.52 from at least $8.36, missing the Wall Street consensus of $8.55. The firm affirmed its adjusted EPS outlook of at least $9 for FY26, compared to the estimate of $8.94. This divergence between the strong quarterly operational metrics and the cautious full-year GAAP forecast drove the sell-off, as analysts cited Reuters noted that investors had anticipated a more aggressive guidance increase.

Membership Growth Drives Revenue

Humana’s revenue growth was underpinned by significant expansion in its Medicare Advantage (MA) membership base. Total medical membership reached 17.91 million at the end of the quarter, up from 14.84 million a year ago. Individual MA membership surged 23% to 6.45 million from 5.23 million, while total Medicare members grew to 11.13 million from 8.23 million. For fiscal 2026, Humana expects individual MA membership growth of approximately 25% over 2025, along with Group MA growth of roughly 150,000 members and Individual Medicare stand-alone PDP growth of about 1 million.

Operational Efficiency Improves

Cost management remained a key highlight of the quarter. The insurance segment benefit ratio stood at 91.2%, consistent with expectations of slightly above 91%. The adjusted consolidated operating cost ratio decreased by 120 basis points year-over-year to 9.7%, while the Insurance segment operating cost ratio fell by the same margin to 7.1%. These improvements were driven by operating leverage from membership and revenue growth, alongside tactical cost-cutting and transformation efforts. Humana reaffirmed its FY26 Insurance segment benefit-ratio outlook of 92.75%, plus or minus 25 basis points, and its consolidated operating cost-ratio outlook of 10%, plus or minus 25 basis points.

What the Numbers Show

The market’s negative reaction underscores the growing scrutiny on health insurers’ ability to sustain margins amid regulatory pressures. While Humana demonstrated effective cost control with a 120-basis point reduction in operating costs, the decision to lower GAAP EPS guidance by nearly $2 suggests underlying volatility or one-time charges not reflected in the adjusted metrics. The affirmation of only modest adjusted EPS growth, despite a 23% surge in individual MA membership, indicates that new member acquisition may be coming at a higher initial cost or that rate relief is less favorable than peers like UnitedHealth Group experienced. Investors are clearly prioritizing forward-looking GAAP profitability over adjusted operational beats, signaling a shift in sentiment towards stricter valuation standards for managed care providers.

Humana Healthcare Research (HHR) has published a new study in Health Affairs Scholar finding that favorable selection in Medicare Advantage (MA) is substantially lower than estimates previously cited by the Medicare Payment Advisory Commission (MedPAC). The research suggests that the impact of favorable selection on MA payments may be smaller than current policy debates indicate, driven by a methodological refinement that utilizes comprehensive encounter data rather than extrapolation from limited subsets.

The study analyzed data from the full MA population between 2020 and 2022. By evaluating this complete dataset directly, HHR estimated favorable selection at 4.9%-5.8%. This figure represents a significant downward revision from the 10%-15% range frequently referenced in policy discussions and earlier MedPAC analyses. The primary driver of this discrepancy was the shift from relying on external studies and limited enrollee subsets to using comprehensive encounter data for direct evaluation.

Key Findings

The core findings of the HHR study are summarized below:

The lower estimates were achieved through a single methodological refinement: the use of comprehensive encounter data to evaluate the full MA population directly. This approach contrasts with prior methods that relied on extrapolation derived from external studies and a limited subset of enrollees. The findings imply that policy assumptions based on higher favorable selection rates may overstate the financial impact on MA payments.

Implications for Payment Policy

Dr. Sanjay Shetty, President of CenterWell, Humana’s health services organization, stated that the study contributes important new evidence to the Medicare Advantage payment conversation. He noted that the substantial reduction in estimates resulting from a single methodological change suggests there is still more to learn about measuring this complex issue. The findings highlight the value of comprehensive data and the importance of continued research to inform MA payment policy.

More broadly, the study demonstrates that full-population comparisons can produce more grounded estimates. This enables extrapolations that are more directly informed by the actual MA population rather than inferred from smaller samples. The research underscores the need for continued methodological refinement in assessing favorable selection to ensure accurate policy formulation.